Guardian Pharmacy Services Reiterates 2025 Revenue Guidance of $1.45 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy GRDN?
Source: Businesswire
- 2025 Revenue Guidance: Guardian Pharmacy Services reiterates its 2025 revenue guidance of $1.43 billion to $1.45 billion, with anticipated 2026 revenue projected between $1.40 billion and $1.42 billion, reflecting the company's confidence in navigating upcoming drug pricing reforms.
- Adjusted EBITDA Growth: The company expects adjusted EBITDA for 2026 to range from $115 million to $118 million, representing approximately 11% year-over-year growth from 2025 guidance, indicating ongoing operational improvements and enhanced profitability.
- New Pharmacy Acquisition: Guardian completed the acquisition of a pharmacy location in Montana, which, while modest in scale, strategically positions the company for market expansion and strengthens its competitive edge in the long-term care sector.
- CEO Strategic Commentary: CEO Fred Burke emphasized that the company has focused on strengthening its business over the past year and expects to maintain a low double-digit adjusted EBITDA growth trajectory in 2026, showcasing its preparedness for market changes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRDN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRDN
Wall Street analysts forecast GRDN stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 33.150
Low
34.00
Averages
34.50
High
35.00
Current: 33.150
Low
34.00
Averages
34.50
High
35.00
About GRDN
Guardian Pharmacy Services, Inc. is a long-term care pharmacy services company. Through its locally based business model, it partners with long-term care facilities (LTCF0073) to deliver medications, and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. Through its locally based pharmacies, the Company utilizes a complex, technology-enabled platform to manage the dispensing and administration of prescriptions to residents of LTCFs over the full prescription lifecycle in order to manage medication risk. Its Guardian Compass platform offers insights to enhance efficiency for its pharmacies, including proprietary real-time operational dashboards and metrics. Its suite of GuardianShield products offers customer and clinical services that benefit both the residents it serves and their caregivers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Guardian Pharmacy Services to Present at Raymond James Conference
- Conference Schedule: Guardian Pharmacy Services will present at the Raymond James Institutional Investors Conference on March 2 at 1:40 p.m. Eastern Time, showcasing its expertise in long-term care pharmacy services.
- Webcast Availability: The session will feature a live audio webcast accessible via the company's website, with a replay available for 90 days post-event, ensuring that investors who cannot attend live can still access the information.
- Company Background: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to enhancing care quality and improving medication adherence through partnerships with long-term care facilities, ultimately reducing care costs.
- Service Coverage: As of September 30, 2025, Guardian operates over 50 pharmacies nationwide, serving nearly 204,000 residents, demonstrating its significant impact and commitment to the long-term care market.
See More
Guardian Pharmacy Services to Release Q4 and Full-Year 2025 Financial Results
- Earnings Release Schedule: Guardian Pharmacy Services will announce its fourth quarter and full-year 2025 financial results after market close on March 11, 2026, providing investors with critical financial performance data to assess the company's operational status.
- Conference Call Details: Management will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results, allowing investors to participate via audio webcast or designated phone numbers, ensuring transparency and timeliness of information.
- Replay Availability: A replay of the call will be available for approximately 60 days after its conclusion, enabling investors who could not attend in real-time to access important information, thereby enhancing communication between the company and its investors.
- Company Background: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to partnering with long-term care facilities to deliver medications and technology-enabled services aimed at reducing care costs and improving clinical outcomes, serving approximately 204,000 residents.
See More
Guardian Pharmacy Services Schedules Q4 2025 Earnings Release
- Earnings Release Announcement: Guardian Pharmacy Services, Inc. has announced that it will release its fourth quarter and full-year 2025 financial results after market close on March 11, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: Management will host a conference call at 4:30 p.m. Eastern Time to discuss the results, with participants able to join via audio webcast or by dialing designated numbers, ensuring timely access to critical information for investors.
- Replay Availability: A replay of the call will be available shortly after its completion and will remain accessible for approximately 60 days, enhancing information accessibility and aiding investors in analyzing the company's financial performance and outlook.
- Company Overview: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy services companies, dedicated to partnering with long-term care facilities to deliver medications and technology-enabled services that improve medication adherence and clinical outcomes, underscoring its significant position in the industry.
See More
Guardian Pharmacy Services Projects $1.40B to $1.42B Revenue for 2026
- Revenue Outlook: Guardian Pharmacy Services expects its 2026 revenue to range between $1.40 billion and $1.42 billion, indicating that drug pricing reforms and wholesale acquisition cost reductions will limit revenue growth.
- EBITDA Growth: The company anticipates adjusted EBITDA for 2026 to be between $115 million and $118 million, representing approximately 11% year-over-year growth from 2025 guidance, showcasing the strength of its operating model and future visibility.
- 2025 Guidance Reiteration: Guardian reaffirms its 2025 revenue guidance of $1.43 billion to $1.45 billion and adjusted EBITDA guidance of $104 million to $106 million, reflecting confidence in its future performance.
- Market Reaction: Following the earnings release, Guardian's stock rose 1.98% in after-hours trading to $31.88, indicating a positive investor sentiment towards the company's outlook.
See More
Guardian Pharmacy Services Reiterates 2025 Revenue Guidance of $1.45 Billion
- 2025 Revenue Guidance: Guardian Pharmacy Services reiterates its 2025 revenue guidance of $1.43 billion to $1.45 billion, with anticipated 2026 revenue projected between $1.40 billion and $1.42 billion, reflecting the company's confidence in navigating upcoming drug pricing reforms.
- Adjusted EBITDA Growth: The company expects adjusted EBITDA for 2026 to range from $115 million to $118 million, representing approximately 11% year-over-year growth from 2025 guidance, indicating ongoing operational improvements and enhanced profitability.
- New Pharmacy Acquisition: Guardian completed the acquisition of a pharmacy location in Montana, which, while modest in scale, strategically positions the company for market expansion and strengthens its competitive edge in the long-term care sector.
- CEO Strategic Commentary: CEO Fred Burke emphasized that the company has focused on strengthening its business over the past year and expects to maintain a low double-digit adjusted EBITDA growth trajectory in 2026, showcasing its preparedness for market changes.
See More
Guardian Pharmacy Confirms Participation in 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation Confirmation: Guardian Pharmacy Services, Inc. has confirmed its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 14 in San Francisco, showcasing its leadership in long-term care pharmacy services, which is expected to attract investor interest.
- Investor Meeting Schedule: The company's leadership team will present at 4:30 p.m. PT on the same day, providing in-depth insights into the company's strategies and future developments, aimed at boosting investor confidence and enhancing shareholder relations.
- Live Webcast and Replay: The session will be available via live audio webcast, allowing investors to listen in real-time, with a replay accessible for 30 days post-event, ensuring that those unable to attend live can still access critical information.
- Service Network Expansion: With over 53 pharmacies nationwide, Guardian is dedicated to providing exceptional service to nearly 204,000 residents, demonstrating its strong influence and ongoing growth potential in the long-term care market.
See More
Guardian Pharmacy Services to Present at Raymond James Conference
- Conference Schedule: Guardian Pharmacy Services will present at the Raymond James Institutional Investors Conference on March 2 at 1:40 p.m. Eastern Time, showcasing its expertise in long-term care pharmacy services.
- Webcast Availability: The session will feature a live audio webcast accessible via the company's website, with a replay available for 90 days post-event, ensuring that investors who cannot attend live can still access the information.
- Company Background: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to enhancing care quality and improving medication adherence through partnerships with long-term care facilities, ultimately reducing care costs.
- Service Coverage: As of September 30, 2025, Guardian operates over 50 pharmacies nationwide, serving nearly 204,000 residents, demonstrating its significant impact and commitment to the long-term care market.
See More
Guardian Pharmacy Services to Release Q4 and Full-Year 2025 Financial Results
- Earnings Release Schedule: Guardian Pharmacy Services will announce its fourth quarter and full-year 2025 financial results after market close on March 11, 2026, providing investors with critical financial performance data to assess the company's operational status.
- Conference Call Details: Management will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results, allowing investors to participate via audio webcast or designated phone numbers, ensuring transparency and timeliness of information.
- Replay Availability: A replay of the call will be available for approximately 60 days after its conclusion, enabling investors who could not attend in real-time to access important information, thereby enhancing communication between the company and its investors.
- Company Background: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to partnering with long-term care facilities to deliver medications and technology-enabled services aimed at reducing care costs and improving clinical outcomes, serving approximately 204,000 residents.
See More
Guardian Pharmacy Services Schedules Q4 2025 Earnings Release
- Earnings Release Announcement: Guardian Pharmacy Services, Inc. has announced that it will release its fourth quarter and full-year 2025 financial results after market close on March 11, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: Management will host a conference call at 4:30 p.m. Eastern Time to discuss the results, with participants able to join via audio webcast or by dialing designated numbers, ensuring timely access to critical information for investors.
- Replay Availability: A replay of the call will be available shortly after its completion and will remain accessible for approximately 60 days, enhancing information accessibility and aiding investors in analyzing the company's financial performance and outlook.
- Company Overview: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy services companies, dedicated to partnering with long-term care facilities to deliver medications and technology-enabled services that improve medication adherence and clinical outcomes, underscoring its significant position in the industry.
See More
Guardian Pharmacy Services Projects $1.40B to $1.42B Revenue for 2026
- Revenue Outlook: Guardian Pharmacy Services expects its 2026 revenue to range between $1.40 billion and $1.42 billion, indicating that drug pricing reforms and wholesale acquisition cost reductions will limit revenue growth.
- EBITDA Growth: The company anticipates adjusted EBITDA for 2026 to be between $115 million and $118 million, representing approximately 11% year-over-year growth from 2025 guidance, showcasing the strength of its operating model and future visibility.
- 2025 Guidance Reiteration: Guardian reaffirms its 2025 revenue guidance of $1.43 billion to $1.45 billion and adjusted EBITDA guidance of $104 million to $106 million, reflecting confidence in its future performance.
- Market Reaction: Following the earnings release, Guardian's stock rose 1.98% in after-hours trading to $31.88, indicating a positive investor sentiment towards the company's outlook.
See More
Guardian Pharmacy Services Reiterates 2025 Revenue Guidance of $1.45 Billion
- 2025 Revenue Guidance: Guardian Pharmacy Services reiterates its 2025 revenue guidance of $1.43 billion to $1.45 billion, with anticipated 2026 revenue projected between $1.40 billion and $1.42 billion, reflecting the company's confidence in navigating upcoming drug pricing reforms.
- Adjusted EBITDA Growth: The company expects adjusted EBITDA for 2026 to range from $115 million to $118 million, representing approximately 11% year-over-year growth from 2025 guidance, indicating ongoing operational improvements and enhanced profitability.
- New Pharmacy Acquisition: Guardian completed the acquisition of a pharmacy location in Montana, which, while modest in scale, strategically positions the company for market expansion and strengthens its competitive edge in the long-term care sector.
- CEO Strategic Commentary: CEO Fred Burke emphasized that the company has focused on strengthening its business over the past year and expects to maintain a low double-digit adjusted EBITDA growth trajectory in 2026, showcasing its preparedness for market changes.
See More
Guardian Pharmacy Confirms Participation in 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation Confirmation: Guardian Pharmacy Services, Inc. has confirmed its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 14 in San Francisco, showcasing its leadership in long-term care pharmacy services, which is expected to attract investor interest.
- Investor Meeting Schedule: The company's leadership team will present at 4:30 p.m. PT on the same day, providing in-depth insights into the company's strategies and future developments, aimed at boosting investor confidence and enhancing shareholder relations.
- Live Webcast and Replay: The session will be available via live audio webcast, allowing investors to listen in real-time, with a replay accessible for 30 days post-event, ensuring that those unable to attend live can still access critical information.
- Service Network Expansion: With over 53 pharmacies nationwide, Guardian is dedicated to providing exceptional service to nearly 204,000 residents, demonstrating its strong influence and ongoing growth potential in the long-term care market.
See More
